Patient ID	Patient Name		Birth Date	Sex	Age
321	PCONS, TESTING		1991-05-15	F	32
Order Number	**Client Order Number**	**Ordering Physician**	**Report Notes**		
X100427016	X100427016	TESTING			
Account Information		**Collected**			
C7028845 DLMP Jacksonville		15 Aug 2023 07:00			

Leukemia/Lymphoma Immunopheno, B

Interpretation

1 MCF

Final Diagnosis:
Peripheral blood, flow cytometric immunophenotyping: Cellular specimen with increased myeloid linearge blasts, 17% (manual differential)

Microscopic Description:
There is an increase in myeloid-lineage blasts that, by this analysis, are quantitatively insufficient to warrant an unequivocal diagnosis of acute myeloid leukemia. Blast cell percentages estimated by flow cytometry are affected by specimen processing and gating and, therefore, may differer significantly from those estimated by morphologic review. The differential diagnosis includes acute myeloid leukemia, a myelodysplastic syndrome, a myeloproliferative neoplasm, a mixed myelodysplastic/myeloproliferative neoplasm, treated or recurrent acute leukemia or other myeloid neoplasms, or sampling bias.

Special Studies:
WBC: 10.0 x 10(9)/L
%Lymphs (CBC/automated differential): 29.55% #Lymphs (CBC/automated differential): 2.96 x 10(9)/L

Results:
Blasts: Increased.
Express: CD7, CD13, CD33, CD34, CD38 (partial), CD45 (dim), CD56, CD117, HLA-DR, cCD22 (partial), cMPO (partial),. Do not express: Kappa, Lambda, CD2, CD3, CD10, CD15, CD16, CD19, CD36, CD64, cCD3, cCD79a, nTdT,. Estimated size (by manual slide differential): 17.4%

B-cells: No monotypic; normal expression pattern of CD19, CD10, surface kappa and lambda.

T-cells/NK-cells: No aberrant phenotype by CD3 and CD16.

Quality Assessment: Specimen received within validated guidelines.

Flow cytometry analysis performed with antibodies to the following antigens: Triage panel: CD3, CD10, CD16, CD19, CD34, CD45 and kappa and lambda surface light chains. Acute panel: CD2, CD7, CD13, CD15, CD33, CD36, CD38, CD56, CD117 and HLA-DR. MPO/TdT panel: cytoplasmic CD3, CD13, cytoplasmic CD22, CD34, CD45, cytoplasmic CD79a, cytoplasmic MPO and nuclear TdT.

Reviewed and interpreted by: ANN ESCALLON

Received: 15 Aug 2023 10:25 **Reported:** 16 Aug 2023 08:04

Laboratory Notes

1 This test was developed using an analyte specific reagent. Its performance characteristics were determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

Performing Site Legend

Code	Laboratory	Address	Lab Director	CLIA Certificate
MCF	Mayo Clinic Jacksonville Clinical Lab	4500 San Pablo Rd, Jacksonville, FL 32224	Jeffrey Dlott MD	10D0269502